Anne‐Marie Mes‐Masson

The paper investigates five BRIP1/FANCJ variants for their clinical relevance in breast and ovarian cancer, finding three likely damaging variants associated with cellular sensitivity to chemotherapy drugs.

This study optimizes vitrification protocols to enhance the preservation of ex vivo 3D tumor models, achieving high proliferative capacity retention.

This study shows BRCA mutations alter ovarian stromal structure by promoting fibroblast senescence and myofibroblastic transformation, creating a metastatic niche for early ovarian cancer.

The paper analyzes germline DNA repair gene variants in BRCA1 and BRCA2 families to assess the prevalence of damaging variants in DNA repair genes beyond established breast cancer predisposing genes.

This study identifies M36, a small-molecule inhibitor of Ran GTPase, showing therapeutic potential in epithelial ovarian cancer through in vitro and in vivo validation.

This study introduces gravity-based microfiltration to isolate CTC clusters, finding they are prevalent in ovarian and colorectal cancer patients.

The paper shows that localized mRNA translation at cell junctions is essential for epithelial cell polarity, with MAGOH and ZO-1 linked to good prognosis in ovarian cancer.

This study shows that senescence in ovarian cancer cells after chemotherapy correlates with better patient survival, suggesting senescence could be a therapeutic target.

This study shows that high 53BP1 levels in ovarian cancer are linked to poor survival and chemotherapy resistance, suggesting it could be a therapeutic target.

This paper identifies FANCI c.1813C>T as a candidate familial ovarian cancer risk allele in a French Canadian population with founder effects.